X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the divestment, Indivior gains the proprietary rights to C4XD’s oral Orexin-1 receptor antagonist, INDV-2000 (C4X_3256) for substance use disorder.
Lead Product(s): C4X_3256
Therapeutic Area: Psychiatry/Psychology Product Name: INDV-2000
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Indivior
Deal Size: $20.4 million Upfront Cash: Undisclosed
Deal Type: Divestment August 01, 2023
Details:
C4XD signs licence agreement with AstraZeneca for the development and commercialisation of NRF2 Activator programme. NRF2 is an important natural regulator, controlling the expression of antioxidant genes, and it plays a key role in cellular defense against external insults.
Lead Product(s): C4X_6665
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: C4X_6665
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $402.0 million Upfront Cash: $2.0 million
Deal Type: Agreement November 28, 2022
Details:
Under the license, Sanofi will develop and commercialise an oral therapy for the treatment of inflammatory diseases. The IL-17 family of cytokines are inducers of inflammation in variety of autoimmune diseases including psoriasis, psoriatic arthritis & ankylosing spondylitis.
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $433.2 million Upfront Cash: $7.3 million
Deal Type: Licensing Agreement April 12, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
